MolecuLight Named Frost & Sullivan's 2026 Global Company of the Year in Wound Imaging
News related to:MolecuLight · 2 min read
PITTSBURGH, Oct. 28, 2026 /CourierPR/ -- MolecuLight, a privately held medical imaging company, has been named Frost & Sullivan's 2026 Global Company of the Year in the wound imaging industry. The recognition highlights MolecuLight's leadership in advancing objective wound assessment, its clinical evidence supporting improved patient outcomes, and its comprehensive training and customer support.
MolecuLight's MolecuLight i:X® and DX® systems, which are FDA-cleared, provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The company's latest offering, MolecuLightDX+, adds thermal imaging capabilities to the mix. These technologies are supported by more than 100 peer-reviewed publications, highlighting their effectiveness and clinical utility.
The Frost & Sullivan award recognizes MolecuLight's ability to integrate bacterial fluorescence imaging, digital wound measurement, and thermal imaging into a handheld platform. This combination helps clinicians identify elevated bacterial burden that might be missed during visual assessment, accurately track changes in wound size, and make more informed treatment decisions. The company's EHR connectivity further supports efficient documentation and continuity of care.
SOC 2 Type II and FIPS certifications reinforce MolecuLight's commitment to secure clinical documentation and robust cybersecurity. The company's commitment to training and customer support is also a key factor in its success.
Frost & Sullivan's assessment evaluates organizations based on innovation, performance, and customer impact. The company's report highlights MolecuLight's ability to bring bacterial fluorescence imaging, digital wound measurement, and thermal imaging together in a single handheld platform. These capabilities help clinicians locate elevated bacterial burden that may be missed during visual assessment, accurately track changes in wound size, and make more informed treatment decisions. EHR connectivity further supports efficient documentation and continuity of care.
The report also emphasizes the clinical evidence supporting improved wound healing, reduced antibiotic use, and fewer infection complications with fluorescence-guided care. MolecuLight's commitment to helping clinical teams use the technology effectively is a key factor in its success. The company's comprehensive training and customer support programs ensure that clinicians can effectively integrate these advanced imaging technologies into their workflows.
MolecuLight's MolecuLight i:X® and DX® systems, which are FDA-cleared, provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The company's latest offering, MolecuLightDX+, adds thermal imaging capabilities to the mix. These technologies are supported by more than 100 peer-reviewed publications, highlighting their effectiveness and clinical utility.
SOC 2 Type II and FIPS certifications reinforce MolecuLight's commitment to secure clinical documentation and robust cybersecurity. The company's commitment to training and customer support is also a key factor in its success.
The award is a testament to MolecuLight's innovative approach to wound imaging and its commitment to improving patient outcomes. The company's technologies and services have made a significant impact on the wound care industry, helping clinicians make more informed treatment decisions and improving patient care.